reports
- Wim Hoste
Tessenderlo FIRST LOOK: Creating a global leader in gelatin/collagen w...
Tessenderlo and Darling Ingredients announced the intention to combine their gelatin & collagen businesses in a joint venture, in which Tessenderlo would have a 15% stake. In light of the difficult market conditions, we welcome the combination which will lead to a gelatin & collagen powerhouse with a global market share of 35-40%. We still appreciate Tessenderlo for the sizeable free cash flow generation and maintain our Accumulate rating for now.
ONWARD Medical Convocation of the 2025 Annual General Meeting of Share...
ONWARD Medical Convocation of the 2025 Annual General Meeting of Shareholders and Proposed Resolutions EINDHOVEN, the Netherlands, April 30, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX ONWRY), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, has today convened the 2025 Annual General Meeting of Shareholders (AGM), which will be held in Amsterdam, the Netherlands, on June 11, 2025. The resolutions propose...
ONWARD Medical Announces Release of 2024 Annual Report
ONWARD Medical Announces Release of 2024 Annual Report EINDHOVEN, the Netherlands, April 28, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announces that its Annual Report for the fiscal year ended December 31, 2024 has been filed with the Dutch Authority for the Financial Markets (AFM). The Company has also released its 2024 Sustainability Report. Last year, the...
Elia Group SANV: 1 director
A director at Elia Group SANV bought 2,580 shares at 90.310EUR and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Lewi
- Thomas Vranken
Onward Medical FIRST LOOK: US ADR program established
Onward has launched an ADR program in the US, allowing American investors to trade Onward shares more easily in USD. Each ADR represents one ordinary Onward share and trades on the OTCQX market under the symbol ONWRY. This move aims to attract US institutional investors, enhance share liquidity, and broaden Onward's shareholder base. While it does not affect the company's cash position or shares outstanding, it could boost visibility, paving another step in the way for a potential future US IPO....
ONWARD Medical Establishes US ADR Program and Begins Trading on OTCQX ...
ONWARD Medical Establishes US ADR Program and Begins Trading on OTCQX Best Market Sponsored Level 1 ADR program facilitates trading by US investors following recent FDA clearance and commercial launch BNY will be ADR depositary bank Ticker symbol for US investors is ONWRY EINDHOVEN, the Netherlands, April 24, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and OTCQX: ONWRY), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilit...
- Wim Lewi
Elia Group Re-initiate with new 95.0 Euro target price
This week, Elia completed its EUR 2.2bn equity package. An earlier 850m private placement (PIPE) through key investors (ATLAS Infrastructure, BlackRock, Canada Pension Plan and Publi-T) was completed with a 1.35bn rights issue at the same issue price 61.88/share. This means that all investors had access to the same conditions. In this note we re-initiate with a new target price of 95 Euro. This equates to a 20% premium the RAB25. While the dilution of the equity raise is higher than expected, s...
- Guy Sips
- Hilde Van Boxstael
- Lynn Hautekeete
- Thomas Couvreur
- Thomas Vranken
- Wim Lewi
- Guy Sips
- Jacob Mekhael
- Thomas Vranken
- Wim Hoste
- Thomas Vranken
Onward Medical 2024 was a transformational year, 2025 to scale commerc...
Onward reported its FY24 business update, which underlined a lot of progress yet no major new surprises, and it reaffirms its outlook of main catalysts. Mgmt. confirmed demand is strong, but no commercial outlook was given yet. We look forward to an FDA label expansion for home use in 2025, while we also expect the pivotal Empower BP trial in blood pressure control to kick off. FY24 topline (€ 1.7m) and net result (€ -35.7m) came in line with our expectations, and with a € 60m cash position we b...
ONWARD Medical Reports Full Year 2024 Financial and Operating Results ...
ONWARD Medical Reports Full Year 2024 Financial and Operating Results and Shares 2025 Year-to-Date Highlights Received FDA authorization and recorded first commercial sales of ARC-EX System Secured strategic investment from Ottobock and extended cash runway for two years Gained exclusive rights to premier brain-computer interface technology EINDHOVEN, The Netherlands, April 01, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with ...
ONWARD Medical publie ses résultats financiers et opérationnels pour l...
ONWARD Medical publie ses résultats financiers et opérationnels pour l’exercice 2024 et partage ses faits marquants du début de l’année 2025 Obtention de l’autorisation de la FDA et premières ventes commerciales du système ARC-EX Investissement stratégique d’Ottobock et extension de la visibilité financière sur deux ans Obtention de droits exclusifs sur une technologie de pointe d’interface cerveau-machine EINDHOVEN, Pays-Bas, 01 avr. 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext : ONWD), société de technologie médicale développant des thérapies innovantes po...
- Lynn Hautekeete
- Wim Lewi
Real Asset Conference feedback 19-20 March 2025
This note gathers feedback from the group meetings and the panels. In total 21 companies were presented in group meetings and/or panels. More than 100 guests found their way to the venue either physical or virtual (only panels). The 2 panels made for informative additions to the C-level meetings and a nice platform for discussion. Wednesday afternoon concentrated 4 experts from Logistic companies (CTP, Montea, VGP, WDP) for an interesting discussion on brownfields: " an answer to the scarcity of...
LEAS LEASINVEST REAL ESTATE SCA
XIOR XIOR STUDENT HOUSING N.V.
COFB COFINIMMO SA
IMMO COMPAGNIE IMMOBILIERE DE BELGIQUE SA
RET RETAIL ESTATES NV
ELI ELIA GROUP SA/NV
MONT MONTEA SCA
AED AEDIFICA SA
QRF QRF COMM
CPINV CARE PROPERTY INVEST SA
ATEB ATENOR S.A.
ASC ASCENCIO SCA
VGP VGP NV
TINC TINC COMM. VA
WDP WAREHOUSES DE PAUW SCA
ECMPA EUROCOMMERCIAL PROPERTIES NV
CTPNV CTP NV
HOMI HOME INVEST BELGIUM
SHUR SHURGARD SELF STORAGE LIMITED
- Anthony Dick
- Michael Foundoukidis
- Thomas Zlowodzki
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
AAL ANGLO AMERICAN PLC
RNO RENAULT SA
APAML APERAM SA
COV COVIVIO SA
OUT1V OUTOKUMPU OYJ
EO FAURECIA SA
SSAB A SSAB AB CLASS A
DAI DAIMLER AG
POM PLASTIC OMNIUM SE
SZG SALZGITTER AG
TYRES NOKIAN RENKAAT OYJ
VOE VOESTALPINE AG
ACX ACERINOX SA
FR VALEO SE
NXT NEXT PLC
BAS BASF SE
VOW3 VOLKSWAGEN AG PREF
ERA ERAMET SA
NDA AURUBIS AG
HM B H&M HENNES & MAURITZ AB CLASS B
RAA RATIONAL AG
ELI ELIA GROUP SA/NV
CIE CIE AUTOMOTIVE S.A.
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
PRY PRYSMIAN S.P.A.
RACE FERRARI NV
RIO RIO TINTO PLC
BHP BHP GROUP LTD
PIRC PIRELLI & C. S.P.A.
AMAG AMAG AUSTRIA METALL AG
GEST GESTAMP AUTOMOCION S.A.
EVD CTS EVENTIM AG & CO. KGAA
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
STLA STELLANTIS N.V.
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
DSFIR KONINKLIJKE DSM N.V.
ALIV SDB AUTOLIV INC.
BRE BREMBO S.P.A.
- Anthony Dick
- Michael Foundoukidis
- Thomas Zlowodzki
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
AAL ANGLO AMERICAN PLC
RNO RENAULT SA
APAML APERAM SA
COV COVIVIO SA
OUT1V OUTOKUMPU OYJ
EO FAURECIA SA
SSAB A SSAB AB CLASS A
DAI DAIMLER AG
POM PLASTIC OMNIUM SE
SZG SALZGITTER AG
TYRES NOKIAN RENKAAT OYJ
VOE VOESTALPINE AG
ACX ACERINOX SA
FR VALEO SE
BAS BASF SE
VOW3 VOLKSWAGEN AG PREF
ERA ERAMET SA
NDA AURUBIS AG
HM B H&M HENNES & MAURITZ AB CLASS B
RAA RATIONAL AG
ELI ELIA GROUP SA/NV
CIE CIE AUTOMOTIVE S.A.
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
PRY PRYSMIAN S.P.A.
RACE FERRARI NV
RIO RIO TINTO PLC
BHP BHP GROUP LTD
PIRC PIRELLI & C. S.P.A.
AMAG AMAG AUSTRIA METALL AG
GEST GESTAMP AUTOMOCION S.A.
EVD CTS EVENTIM AG & CO. KGAA
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
STLA STELLANTIS N.V.
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
DSFIR KONINKLIJKE DSM N.V.
ALIV SDB AUTOLIV INC.
BRE BREMBO S.P.A.
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Sharad Kumar S.P
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Thijs Berkelder
- ING Helpdesk
Benelux Morning Notes
Avantium: Management team change. Belgian telcos: Extra data on Proximus brand mobile plans at no additional cost. Elia: Launch of €1.35bn rights issue and closing of €850m private placement. Randstad: Preliminary preview of 1Q25F results due 23 April. Shell plc: Very solid CMD, attractive outlook for shareholders. Tessenderlo: 2024 in-line with lowered outlook, soft 2025F guidance
- Thomas Vranken
Onward Medical FIRST LOOK: First-in-human implant of new ARC-IM lumbar...
Onward announced the first-in-human use of its new lumbar (lower back) lead for ARC-IM, that could deliver targeted stimulation to restore lower limb mobility (e.g., standing & walking). We see this as an important clinical milestone, while we expect the company to continue to prioritize the commercial launch of ARC-EX and the start of the pivotal Empower BP trial with ARC-IM for blood pressure control. We reiterate our € 10.4 TP and Buy rating.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.